(NASDAQ: VRTX) Vertex Pharmaceuticals's forecast annual revenue growth rate of 9.7% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.35%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.04%.
Vertex Pharmaceuticals's revenue in 2026 is $12,218,000,000.On average, 35 Wall Street analysts forecast VRTX's revenue for 2026 to be $3,375,612,046,100, with the lowest VRTX revenue forecast at $3,222,059,768,815, and the highest VRTX revenue forecast at $3,494,139,175,839. On average, 34 Wall Street analysts forecast VRTX's revenue for 2027 to be $3,701,244,396,111, with the lowest VRTX revenue forecast at $3,335,510,790,214, and the highest VRTX revenue forecast at $4,317,230,143,170.
In 2028, VRTX is forecast to generate $4,109,109,701,230 in revenue, with the lowest revenue forecast at $3,533,986,626,308 and the highest revenue forecast at $4,797,429,992,134.